Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $31.83 Consensus Price Target from Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have earned a consensus recommendation of “Hold” from the nine ratings firms that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $31.8333.

STRO has been the subject of several research reports. Citizens Jmp upgraded Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price objective for the company in a research report on Tuesday, January 20th. Citigroup raised Sutro Biopharma to an “outperform” rating in a report on Tuesday, January 20th. Wedbush restated a “neutral” rating and issued a $100.00 price objective (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. Wall Street Zen cut Sutro Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Monday, December 22nd.

Hedge Funds Weigh In On Sutro Biopharma

Several institutional investors and hedge funds have recently modified their holdings of the company. Jacobs Levy Equity Management Inc. acquired a new stake in Sutro Biopharma during the third quarter worth approximately $387,000. Velan Capital Investment Management LP lifted its stake in shares of Sutro Biopharma by 2.0% during the 3rd quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company’s stock worth $2,709,000 after purchasing an additional 60,000 shares during the period. Bank of America Corp DE boosted its holdings in shares of Sutro Biopharma by 51.3% during the third quarter. Bank of America Corp DE now owns 119,434 shares of the company’s stock worth $104,000 after purchasing an additional 40,488 shares during the last quarter. Shay Capital LLC grew its position in shares of Sutro Biopharma by 20.1% in the third quarter. Shay Capital LLC now owns 312,051 shares of the company’s stock valued at $271,000 after purchasing an additional 52,162 shares during the period. Finally, Two Sigma Investments LP grew its position in shares of Sutro Biopharma by 244.8% in the third quarter. Two Sigma Investments LP now owns 396,785 shares of the company’s stock valued at $345,000 after purchasing an additional 281,717 shares during the period. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Stock Down 4.4%

NASDAQ:STRO opened at $14.92 on Tuesday. Sutro Biopharma has a 52-week low of $5.23 and a 52-week high of $21.25. The stock has a fifty day simple moving average of $11.14 and a 200-day simple moving average of $9.72. The company has a market capitalization of $126.97 million, a PE ratio of -0.57 and a beta of 1.52.

Sutro Biopharma (NASDAQ:STRO) last posted its earnings results on Thursday, November 6th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.25). The business had revenue of $9.69 million for the quarter, compared to analysts’ expectations of $10.14 million. Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%. As a group, equities analysts anticipate that Sutro Biopharma will post -2.92 earnings per share for the current year.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.